Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig (original) (raw)
- Paper
- Published: 29 April 1998
Gene Therapy volume 5, pages 309–319 (1998)Cite this article
- 333 Accesses
- 113 Citations
- 3 Altmetric
- Metrics details
Abstract
Adenoviral vectors deleted of E1 are attractive vehicles for in vivo gene therapy because efficient gene transfer can be achieved. Immune responses to the vector and vector-transduced cells lead to destruction of target cells, inflammation and difficulties with vector readministration. Immune effectors have been identified as CD8+ cytotoxic T lymphocytes, which destroy vector-transduced cells, as well as B cells which secrete neutralizing antibodies and block repeated gene transfer. The central role of CD4+ T cells in the activation of both of these effector functions has focused immunosuppressive strategies towards blockade of costimulatory molecules. We describe in this study a strategy which aims to inhibit CD4+ T cell activation by transiently administering an inhibitor of the CD28/B7 pathway, ie CTLA4Ig, at the time an E1-deleted adenovirus is administered to liver or lung. In lung, CTLA4Ig treatment significantly blocked the formation of neutralizing antibodies, allowing efficient readministration of virus, whereas transgene expression was only moderately prolonged. In contrast, CTLA4Ig did not suppress neutralizing antibody formation in the context of liver gene therapy, but resulted in more stable gene expression. In vitro assays revealed suppression of T cell activation in either organ. This observation suggests that transient inhibition of the CD28/B7 pathway at the time of virus instillation can partially interfere with both arms of the immune response to adenovirus-mediated gene transfer circumventing the need for chronic immune suppression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Institute for Human Gene Therapy, Philadelphia, PA, USA
K Jooss, LA Turka & JM Wilson - Department of Molecular and Cellular Engineering, Philadelphia, PA, USA
K Jooss & JM Wilson - Department of Medicine, The University of Pennsylvania Medical Center, and the Wistar Institute, Philadelphia, PA, USA
LA Turka & JM Wilson
Authors
- K Jooss
You can also search for this author inPubMed Google Scholar - LA Turka
You can also search for this author inPubMed Google Scholar - JM Wilson
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Jooss, K., Turka, L. & Wilson, J. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig.Gene Ther 5, 309–319 (1998). https://doi.org/10.1038/sj.gt.3300595
- Received: 16 July 1997
- Accepted: 03 November 1997
- Published: 29 April 1998
- Issue Date: 01 March 1998
- DOI: https://doi.org/10.1038/sj.gt.3300595